From: Epigenomic response to albuterol treatment in asthma-relevant airway epithelial cells
Variable | Discovery | Validation |
---|---|---|
GALA II ( n = 97) | Obese asthma study (n = 10) | |
Age (years) | 13.9 (11.9–15.6) | 28.0 (24.5–33.5) |
Sex (female) | 46 (47.4) | 8 (80.0) |
Population | ||
Hispanic | 97 (100) | 1 (10.0) |
White | 0 (0) | 6 (60.0) |
Asian | 0 (0) | 2 (20.0) |
Asthma | 67 (69.1) | 5 (50.0) |
Asthma severity | ||
Mild Asthma | 31 (46.3) | NA |
Moderate-to-severe Asthma | 36 (53.7) | NA |
BMI Categories* | ||
Underweight | 4 (4.3) | 0 (0.0) |
Normal | 51 (54.2) | 4 (40.0) |
Overweight | 13 (13.8) | 3 (30.0) |
Obese | 26 (27.7) | 3 (30.0) |
pre-FEV1 (liters)* | 3.0 (2.4–3.5) | NA |
pre-FVC (liters)* | 3.4 (2.7–4) | NA |
FEV1/FVC* | 0.9 (0.9–0.9) | NA |
BDR (%)* | 9.2 (7.2–13.3) | NA |
Total IgE* | 455.1 (174.9–955.7) | NA |
FeNO (ppb) | 28.0 (13.0–50.2) | NA |
Eosinophils (%)* | 0.0 (0.0–0.1) | NA |
Medication use†| ||
SABA | 52 (77.6) | NA |
Any controller medication | 32 (47.8) | NA |